<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604630</url>
  </required_header>
  <id_info>
    <org_study_id>BfArM-4019639/2002</org_study_id>
    <secondary_id>&quot;EPO Stroke Study&quot;</secondary_id>
    <secondary_id>&quot;Ehrenreich EPO Stroke Study&quot;</secondary_id>
    <secondary_id>&quot;Ehrenreich Study&quot;</secondary_id>
    <nct_id>NCT00604630</nct_id>
  </id_info>
  <brief_title>Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke</brief_title>
  <acronym>ESS</acronym>
  <official_title>German Multicenter EPO Stroke Trial (Phase II/III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max-Planck-Institute of Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Max-Planck-Institute of Experimental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, double-blind, placebo-controlled multicenter study is to
      determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral
      artery territory, the effect of a three-day high-dose, intravenous erythropoietin treatment
      on functional outcome up to a follow-up of 90 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological/functional outcome as measured by the Barthel Index (BI)</measure>
    <time_frame>day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) responder</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI)</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS</measure>
    <time_frame>day30, day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale</measure>
    <time_frame>day 1, 3, 7, 30, 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with minimal disability (mRS 0-1)</measure>
    <time_frame>day 30, day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality directly related to stroke</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BI &gt;= 95</measure>
    <time_frame>day 30, day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BI=100</measure>
    <time_frame>day 30, day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with neurological recovery</measure>
    <time_frame>day 3, 7, 30, 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of mRS scores</measure>
    <time_frame>day 30, day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of BI scores</measure>
    <time_frame>day 30, day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of NIH Stroke Scale scores</measure>
    <time_frame>day 30, day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of glial damage markers S100B and GFAP</measure>
    <time_frame>day 1, 2, 3, 4, 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion size (MRI DWI, flair)</measure>
    <time_frame>day 1, day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late recovery index (BI day 90 versus BI day 30)</measure>
    <time_frame>day 30 to day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">522</enrollment>
  <condition>Infarction, Middle Cerebral Artery</condition>
  <condition>Middle Cerebral Artery Stroke</condition>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50ml 0.9% NaCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human erythropoietin alfa</intervention_name>
    <description>40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms</description>
    <arm_group_label>verum</arm_group_label>
    <other_name>ERYPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <description>50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke in the middle cerebral artery territory

          -  Clearly defined time of onset

          -  Confirmed by MRI (DWI, Flair)

          -  NIH Stroke Scale ≥ 5

          -  Age &gt; 18 years

          -  Treatment within 6h after onset of symptoms

          -  Informed consent by patient, relatives or independent physician

          -  Life expectancy &gt; 90 days

        Exclusion Criteria:

          -  Coma or precoma (level of consciousness ≥ 2 in NIH Stroke Scale)

          -  Previous stroke within the same territory

          -  Intracranial or subarachnoidal hemorrhage

          -  Traumatic brain injury or brain operation within the last 4 weeks

          -  Neoplasia, septic embolism, infectious endocarditis

          -  MRI contraindications

          -  Renal failure (i.e. dependent on dialysis)

          -  Known malignant/life-threatening disease

          -  Known myeloproliferative disorder, polycythemia

          -  Known allergy or antibodies against erythropoietin

          -  Participation in other intervention trials

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neurologische Klinik des Städtischen Klinikums Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>D-38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klink, Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>D-28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik, Allgemeines Krankenhaus Celle</name>
      <address>
        <city>Celle</city>
        <zip>D-29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik, Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie, Universität Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik der Georg-August-Universität Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik, Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie der Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.em.mpg.de</url>
    <description>homepage of the Max-Planck-Institute of Experimental Medicine</description>
  </link>
  <link>
    <url>http://www.epo-study.de/index.html</url>
    <description>information about the German Multicenter EPO Stroke Study and previous related trials</description>
  </link>
  <reference>
    <citation>Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4044-9. Epub 2001 Mar 20.</citation>
    <PMID>11259643</PMID>
  </reference>
  <reference>
    <citation>Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 Aug;8(8):495-505.</citation>
    <PMID>12435860</PMID>
  </reference>
  <reference>
    <citation>Lewczuk P, Hasselblatt M, Kamrowski-Kruck H, Heyer A, Unzicker C, Sirén AL, Ehrenreich H. Survival of hippocampal neurons in culture upon hypoxia: effect of erythropoietin. Neuroreport. 2000 Nov 9;11(16):3485-8.</citation>
    <PMID>11095504</PMID>
  </reference>
  <reference>
    <citation>Sirén AL, Knerlich F, Poser W, Gleiter CH, Brück W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 2001 Mar;101(3):271-6.</citation>
    <PMID>11307627</PMID>
  </reference>
  <reference>
    <citation>Herrmann M, Ehrenreich H. Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci. 2003;21(3-4):177-90. Review.</citation>
    <PMID>14530580</PMID>
  </reference>
  <reference>
    <citation>Ehrenreich H, Hasselblatt M, Knerlich F, von Ahsen N, Jacob S, Sperling S, Woldt H, Vehmeyer K, Nave KA, Sirén AL. A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):862-7. Epub 2005 Jan 10.</citation>
    <PMID>15642952</PMID>
  </reference>
  <reference>
    <citation>Sirén AL, Radyushkin K, Boretius S, Kämmer D, Riechers CC, Natt O, Sargin D, Watanabe T, Sperling S, Michaelis T, Price J, Meyer B, Frahm J, Ehrenreich H. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain. 2006 Feb;129(Pt 2):480-9. Epub 2005 Dec 9.</citation>
    <PMID>16339796</PMID>
  </reference>
  <reference>
    <citation>Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, Heinz G, Erdag S, Jahn H, Degner D, Ritzen M, Mohr A, Wagner M, Schneider U, Bohn M, Huber M, Czernik A, Pollmächer T, Maier W, Sirén AL, Klosterkötter J, Falkai P, Rüther E, Aldenhoff JB, Krampe H. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007 Feb;12(2):206-20. Epub 2006 Oct 10.</citation>
    <PMID>17033631</PMID>
  </reference>
  <reference>
    <citation>Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, Sirén AL, Paulus W, Nave KA, Gold R, Bartels C. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007 Oct;130(Pt 10):2577-88. Epub 2007 Aug 29.</citation>
    <PMID>17728357</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>October 21, 2008</last_update_submitted>
  <last_update_submitted_qc>October 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Dr. Hannelore Ehrenreich (MD, DVM), Head of the Division of Clinical Neuroscience</name_title>
    <organization>Max-Planck-Institute of Experimental Medicine</organization>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>EPO</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>ischemia</keyword>
  <keyword>hypoxia</keyword>
  <keyword>antiapoptosis</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>rtPA</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>stroke, middle cerebral artery</keyword>
  <keyword>Ischemic stroke in the middle cerebral artery territory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

